Navigation Links
Ludwig advancements in immunotherapy and epigenetics top scientific program at AACR
Date:4/10/2013

April 10, 2013, New York, NY A dozen Ludwig scientists from around the world presented the latest advancements in basic and clinical cancer research at this week's American Association of Cancer Research (AACR) Annual Meeting 2013. Progress in immunotherapy and epigenetics led the program with important diagnostic and treatment implications for emerging cancer therapy.

"With new immunotherapy agents available to help patients with melanoma, researchers are developing prognostic biomarkers to determine who will benefit most to fully realize the potential of these treatments," explained Jedd D. Wolchok, PhD, MD, director of Ludwig's Collaborative Laboratory at Memorial Sloan-Kettering Cancer Center during his presentations at AACR. "By identifying targeted combinations of agents, the immune response can be improved in certain patients with melanoma, the most dangerous form of skin cancer."

Developments in immunotherapeutic treatment of ovarian cancer was highlighted in a "Meet the Expert" session with George Coukos, PhD, MD, director of the Ludwig Center for Cancer Research of the University of Lausanne. His presentation educated on current progress and future prospects in vaccine and adoptive T-cell therapy development, as well as immunomodulatory therapy tools available for immediate clinical testing. "Ovarian cancer remains a very important therapeutic challenge," commented Dr. Coukos. "With no drugs approved in two decades in the U.S. and no therapeutic targets emerging from deep sequencing analyses, immunotherapy could offer a promising new approach."

Dr. Geoffrey Greene's team at the Ludwig Center at the University of Chicago analyzed epigenetic regulators called microRNAs little pieces of ribonucleic acid that are present in all the cells in the body to better understand treatment challenges of metastasis and chemotherapy resistance in patients with triple negative breast cancer.

"Our research used a novel human tumor xenograft model to better understand the fundamental mechanisms of these tumors," said lead author Huiping Liu, Research Associate, Ben May Department and the Ludwig Center, University of Chicago. "We know that proteins turn genes on and off but so do microRNAs. Our team discovered a small yet influential microRNA known as 30c. When it is present in cells it inhibits metastasis and improves a patient's response to chemotherapy treatment. Our findings may provide a potential new treatment target for this difficult to treat cancer."

From Dr. Bing Ren's laboratory of gene regulation at the Ludwig Institute for Cancer Research in San Diego, post-doctoral fellow Gary Hon, PhD described how adult tissues retain an epigenetic memory of their past development. Further, Dr. Ren tutored conferees about research related to long-range control of gene expression in mammalian cells during an educational session.


'/>"/>

Contact: Rachel Steinhardt
rsteinhardt@licr.org
212-450-1582
Ludwig Institute for Cancer Research
Source:Eurekalert

Related biology news :

1. Ludwig cancer researchers honored among first class of fellows in AACR Academy
2. International Life Sciences Conferences Address Advancements in High-Content Analysis, Sample Preparation, Clinical Trial Supply and Protein and Antibody Engineering
3. High-strength material advancements at Wayne State University may lead to new, life-saving steel
4. P&G Beauty & Grooming to present advancements in skin aging & stress sweat at AAD Meeting
5. Stem cell finding could advance immunotherapy for lung cancer
6. Novel coronavirus well-adapted to humans, susceptible to immunotherapy
7. Epigenetics and epidemiology -- hip, hype and science
8. Not by DNA alone: How the epigenetics revolution is fostering new medicines
9. Sick from stress? Blame your mom… and epigenetics
10. Study finds epigenetics, not genetics, underlies homosexuality
11. Epigenetics shapes fate of brain vs. brawn castes in carpenter ants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/8/2016)... N.C. , March 8, 2016   ... sensor technology, today announced it has secured $11M ... by GII Tech, a new venture fund being ... with additional participation from existing investors TDF Ventures ... the funds to continue its triple-digit growth and ...
(Date:3/3/2016)... DE SOTO, Kansas , March 3, 2016 ... to offer Oncimmune,s Early CDT®-Lung, a blood test ... of lung cancer Early CDT®-Lung test to ... --> Early CDT®-Lung test to its clients ... Oncimmune, a leader in early cancer detection, today ...
(Date:3/1/2016)... , March 1, 2016 /PRNewswire/ ... announced the addition of the  "Global ...  report to their offering. ... the addition of the  "Global Biometric ...  report to their offering. --> ...
Breaking Biology News(10 mins):
(Date:4/29/2016)... ... April 29, 2016 , ... Proove ... excited to announce the launch of the Proove Health Foundation . The ... education to promote the use of personalized medicine for tackling the nation’s most-pressing ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... fundamentals to transform technology into a viable company, CereScan’s CEO, John Kelley, joined ... Kelley, a recognized leader and mentor in the Denver area business community, shared ...
(Date:4/29/2016)... Elekta is pleased to announce ... industry-leading treatment planning software, is available for clinical release. ... version 5.11 provides significant performance speed enhancements over ... to four times faster than in previous versions of ... standard Monte Carlo algorithm, users ...
(Date:4/28/2016)... Rocky Hill, Conn. (PRWEB) , ... April 28, ... ... source of financing and ongoing support for Connecticut's innovative, growing companies, today announced ... early-stage digital health and financial technology (fintech) companies. , “VentureClash looks ...
Breaking Biology Technology: